BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Trial Profile

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Risankizumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMvent
  • Sponsors AbbVie
  • Most Recent Events

    • 09 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 21 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 07 Mar 2016 Planned initiation date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top